Search results
Is ASLAN Pharmaceuticals (ASLN) Stock Outpacing Its Medical Peers This Year?
Zacks via Yahoo Finance· 1 year agoInvestors interested in Medical stocks should always be looking to find the best-performing...
Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?
Zacks via Yahoo Finance· 2 months agoInvestors interested in Medical stocks should always be looking to find the best-performing...
ASLAN Pharmaceuticals Limited's (NASDAQ:ASLN) recent 25% pullback adds to one-year year losses,...
Simply Wall St. via Yahoo Finance· 1 year agoKey Insights Given the large stake in the stock by institutions, ASLAN Pharmaceuticals' stock price...
Bears are Losing Control Over ASLAN Pharmaceuticals Ltd. (ASLN), Here's Why It's a 'Buy' Now
Zacks via Yahoo Finance· 1 year agoASLAN Pharmaceuticals Ltd. (ASLN) witnesses a hammer chart pattern, indicating support found by the...
ASLAN (ASLN) Down 25% on Mixed Results From Skin Disease Study
Zacks via Yahoo Finance· 11 months agoASLAN (ASLN) reports mixed results from a mid-stage study of eblasakimab in adult patients with...
ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study
Zacks via Yahoo Finance· 3 months agoASLAN (ASLN) rises on upbeat initial data from a phase II study of eblasakimab in patients with...
What's Going On With ASLAN Pharmaceuticals Stock Today?
Benzinga via Yahoo Finance· 11 months agoASLAN Pharmaceuticals Ltd (NASDAQ: ASLN) released topline data from its TREK-AD Phase 2b...
ASLAN Pharma Starts Eblasakimab Program In Dupixent Treated Dermatitis Patients
Benzinga via Yahoo Finance· 2 years agoASLAN Pharmaceuticals (NASDAQ: ASLN) plans to initiate a new clinical trial of eblasakimab for...
ASLAN Pharmaceuticals Presents New Data From Atopic Dermatitis Candidate
Benzinga via Yahoo Finance· 2 years agoASLAN Pharmaceuticals (NASDAQ: ASLN) announced the presentation of new translational eblasakimab...
Apellis' (APLS) Q3 Earnings Miss Estimates, Revenues Top Mark
Zacks via Yahoo Finance· 2 years agoApellis Pharmaceuticals, Inc. APLS reported a loss per share of $1.75 for third-quarter 2022, wider...